The FDA has approved Blujepa for the treatment of uncomplicated urogenital gonorrhea caused by susceptible strains of Neisseria gonorrhoeae.

Trauma severity predicted SSI risk and ertapenem prophylaxis reduced traumatic wound infection rates following exploratory laparotomy for visceral perforation.

COVID-19, RSV, and influenza immunizations show continued safety and substantial effectiveness against hospitalization across various populations.

Elevated lactate levels and hypotension independently predicted higher in-hospital mortality in critically ill adults with COVID-19.

A system-level, multifactorial intervention significantly reduced the risk of maternal infection outcomes, according to a recent study.

HCC risk remains after DAA-cured HCV in individuals with HIV, but the annual probability of developing HCC declines over 6 years.

Early measles vaccination rates among infants aged 6 to 11 months in Texas increased sharply during the 2025 measles outbreak, suggesting families and clinicians responded to the updated CDC ...

The recalled ReBoost Nasal Spray has a lot number of 224268 and an expiration date of December 2027. MediNatura New Mexico is recalling 1 lot of ReBoost Nasal Spray (NDC# 62795-4005-9; UPC# 787647 ...